Newsroom

Keep up with our latest news.

July 2022

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

All
Press Releases

November 06, 2024

Press Releases

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements Read More

September 23, 2024

Press Releases

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 Read More

September 03, 2024

Press Releases

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference Read More

August 06, 2024

Press Releases

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements Read More

August 06, 2024

Press Releases

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 Read More

May 07, 2024

Press Releases

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference Read More

Pages: 12345678910

Investor Resources

Follow our journey with our latest Investor Resources

Press Releases

Read the latest News Releases for Investors

Events

Browse the calendar to view Investor related events and announcements. Webcasts and presentations that have been archived are available by viewing historical event details.

SEC Filings

Review all of Elevation's SEC filings

Track our progress

Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.